Paragon’s Maryland facility adds Passage Bio’s manufacturing suite

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/zimmytws)
(Image: Getty/zimmytws)

Related tags: Paragon Bioservices, Manufacturing, biomanufacturing, Clinical supply, Supply and demand, Rare disease, facility, Catalent

Paragon and Passage Bio enter a collaboration agreement to develop a dedicated manufacturing suite at the former’s Maryland facility, as the latter’s gene therapy candidates enter the clinic.

Passage Bio, a genetic medicines company focused on developing adeno associated virus (AAV) delivered gene therapies, will work with Paragon Gene Therapy, a contract development and manufacturing organization (CDMO) and unit of Catalent​, to develop a manufacturing suite for clinical and commercial supply production.

In 2018, Paragon built the 150,000-square-foot biomanufacturing facility​ for the production of clinical batches of gene therapies, which is equipped with 500L and 2000L single-use bioreactors. Previously, the site has worked on the production of rare disease therapeutics.

Stephen Squinto, co-founder and interim CEO of Passage, said in a statement, “We understand that manufacturing is a critical part of a successful gene therapy program and securing our own dedicated manufacturing suite, through this new strategic partnership with Paragon, is a key facet of our business plan.”

Earlier in 2019, Passage completed a $115.5m (€102.6m) Series A financing to advance its portfolio of five product candidates.

Passage’s lead gene therapy candidates will target rare, monogenic diseases, in the form of GM1 gangliosidosis, frontotemporal dementia, and Krabbe disease. The company’s therapies for the diseases will enter the clinic in 2020, and the company also has the option to license seven additional indications.

Both companies involved in collaboration are based in the US, with Paragon housing the current good manufacturing practice (cGMP) manufacturing suite at its Baltimore, Maryland facility. Passage, based in Philadelphia, Pennsylvania, is located near the suite, which is expected to be operational in 2020.

Production of clinical and commercial supply for Passage Bio will use the iCELLis single-use, fixed-bed bioreactor technology to provide scalable manufacturing and cultivation of adherent cells. The company stated that this technology enables it to produce clinical and commercial-scale volumes to meet demand.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Related suppliers

Follow us


View more